BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of C$5.25 and traded as high as C$5.79. BriaCell Therapeutics shares last traded at C$5.57, with a volume of 21,391 shares trading hands.
BriaCell Therapeutics Price Performance
The stock has a fifty day moving average price of C$5.22 and a 200-day moving average price of C$5.25. The company has a market cap of C$48.64 million, a PE ratio of -0.80 and a beta of 1.53.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Read More
- Five stocks we like better than BriaCell Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
